Publications by authors named "Olumide Babajide Gbolahan"
Article Synopsis
- A study evaluated the safety and effectiveness of combining yttrium-90 radioembolization (Y90-RE) with immune checkpoint inhibitors in advanced hepatocellular carcinoma (HCC) patients treated from 2016 to 2022.
- 19 patients were included, with two groups receiving either atezolizumab/bevacizumab or nivolumab, showing similar outcomes in treatment responses and adverse events, though more ECOG ≥ 2 patients were in the nivolumab group.
- The median overall survival was 12.9 months overall, with 16.4 months for nivolumab and 10.7 months for atezolizumab/bevacizumab, indicating that the combination therapy was well
Intensive chemotherapeutic protocols and allogeneic stem cell transplantation continue to represent the mainstay of acute myeloid leukemia (AML) treatment. Although this approach leads to remissions in the majority of patients, long-term disease control remains unsatisfactory as mirrored by overall survival rates of approximately 30%. The reason for this poor outcome is, in part, due to various toxicities associated with traditional AML therapy and the limited ability of most patients to tolerate such treatment.
View Article and Find Full Text PDF